140 related articles for article (PubMed ID: 2747742)
1. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Jan; 32(1):46-52. PubMed ID: 2747742
[TBL] [Abstract][Full Text] [Related]
2. The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against Candida species.
Bulo AN; Bradley SF; Kauffman CA
Mycoses; 1989 Mar; 32(3):151-7. PubMed ID: 2733727
[TBL] [Abstract][Full Text] [Related]
3. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
Smith KR; Lank KM; Dismukes WE; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):588-92. PubMed ID: 1655435
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro antifungal susceptibility studies with 30 serotype A and B isolates of Candida albicans.
Shadomy S; Shadomy HJ
Diagn Microbiol Infect Dis; 1991; 14(1):21-2. PubMed ID: 2013207
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B.
Meunier F; Lambert C; Van der Auwera P
J Antimicrob Chemother; 1989 Sep; 24(3):325-31. PubMed ID: 2681118
[TBL] [Abstract][Full Text] [Related]
6. Effect of cilofungin on phagocytosis and intracellular killing of Candida albicans by human neutrophils.
Richardson MD; Scott G; Shankland GS
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):22-6. PubMed ID: 1563379
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species.
Villareal KM; Cook RA; Galgiani JN; Wenzel RP; Pappas PG; Pottage JC; Gallis HA; Crane LR
Diagn Microbiol Infect Dis; 1994 Feb; 18(2):89-94. PubMed ID: 8062537
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity in vitro of cilofungin (LY 121019) with other agents used for treatment of deep-seated Candida infections.
Rennie RP; Hellman L
Mycoses; 1989 Mar; 32(3):145-50. PubMed ID: 2733726
[TBL] [Abstract][Full Text] [Related]
9. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Infect Chemother; 2009 Feb; 15(1):1-5. PubMed ID: 19280292
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergy testing of anidulafungin with fluconazole, tioconazole, 5-flucytosine and amphotericin B against some Candida spp.
Rosato A; Piarulli M; Schiavone BI; Montagna MT; Caggiano G; Muraglia M; Carone A; Franchini C; Corbo F
Med Chem; 2012 Jul; 8(4):690-8. PubMed ID: 22530916
[TBL] [Abstract][Full Text] [Related]
11. Synergy between cilofungin and amphotericin B in a murine model of candidiasis.
Hanson LH; Perlman AM; Clemons KV; Stevens DA
Antimicrob Agents Chemother; 1991 Jul; 35(7):1334-7. PubMed ID: 1929290
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Moore CB; Oakley KL; Denning DW
Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
[TBL] [Abstract][Full Text] [Related]
13. Activity of cilofungin (LY121019) against Candida species in vitro.
Odds FC
J Antimicrob Chemother; 1988 Dec; 22(6):891-7. PubMed ID: 3243737
[TBL] [Abstract][Full Text] [Related]
14. In-vitro effects of cilofungin (LY121019), amphotericin B and amphotericin B-deoxycholate on human polymorphonuclear leucocytes.
Van der Auwera P; Meunier F
J Antimicrob Chemother; 1989 Nov; 24(5):747-63. PubMed ID: 2557318
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis.
Denning DW; Stevens DA
Antimicrob Agents Chemother; 1991 Jul; 35(7):1329-33. PubMed ID: 1929289
[TBL] [Abstract][Full Text] [Related]
16. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents.
Pfaller M; Gordee R; Gerarden T; Yu M; Wenzel R
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):564-7. PubMed ID: 2504601
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of Candida species to cilofungin (LY-121019).
Torres-Rodriguez JM; Carrillo-Muñoz A; Gallach-Bau C; Madrenys N
Mycoses; 1989 Jun; 32(6):316-8. PubMed ID: 2779613
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents.
Pfaller MA; Wey S; Gerarden T; Houston A; Wenzel RP
Diagn Microbiol Infect Dis; 1989; 12(1):1-4. PubMed ID: 2714066
[TBL] [Abstract][Full Text] [Related]
19. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
20. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
Karlowsky JA; Hoban DJ; Zhanel GG; Goldstein BP
Int J Antimicrob Agents; 2006 Feb; 27(2):174-7. PubMed ID: 16414247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
